Diabetes Epidemiology

Diabetes Epidemiology Data (scroll down for additional slides)

  • Epi Overview (US Market)

    Seagrove estimates approximately 29 million people in the US have diagnosed diabetes, with 1.9 million having the Type 1 form. At end end of 2022, there were over 3.1 million people using a CGM domestically with the highest rates of growth occurring in the T2D segment.

  • Epi Overview (WW Market)

    Seagrove estimates that there are approximately 16 million people worldwide with T1D and 319 million people with T2D. Prevalence rates for both T1D and T2D vary significantly by region depending upon lifestyle factors and genetics with Northern Europe having the highest rates of T1D.

  • US Epidemiology Detail

    Seagrove estimates that there are over 1.9M people in the US living with Type 1 diabetes (over 600K are using insulin pumps) and 27 million people who have been diagnosed with Type 2 diabetes. There are a total of about 7 million people who use insulin on a daily basis.

  • US Epidemiology Segments

    Therapeutic options for T2D include insulin, GLP-1s, SGLT-2s and older oral medications like metformin. Seagrove estimates that stronger GLP-1s coming to market could significantly reduce the amount of people that progress to insulin therapy.

  • Prevalence of Diabetes by Age Groups

    Type 2 diabetes skews to older age groups with over 80% in this segment being age 40 or older. Type 1 diabetes is typically diagnosed in people age 18 and younger with newer medical devices (like pumps and CGMs) seeking age indications down to two years old.

  • Diabetes Co-Morbid Conditions

    There is a high degree of overlap between diabetes and other chronic conditions, especially high cholesterol, hypertension and obesity. Many new therapeutic options are attempting to treat multiple conditions by lowering A1C, body weight and the risk for cardiovascular events.